We at TIEFEENBACHER PHARMACEUTICALS aim to improve peoples´ lives around the world by making medicines better affordable, better available, and better than before! That´s why we are excited to share that we have successfully prepared the launch of the generic versions of Abiraterone and the value-added product Abiraterone/Prednisolone for a market entry in Europe.

For the mono product Abiraterone, we were able to achieve a day one launch after patent expiration, making this important therapy finally more affordable for patients around the world. With the combination product Abiraterone/Prednisolone we offer a value-added product which comes in a special combi blister packaging improving patients´ compliance, physicians´ convenience, and protecting the environment.

Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners. A launch in further international markets will follow soon.

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu 

TIEFENBACHER PHARMACEUTICALS is as a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com